ChaoWang Ph.D.

IP Legal Intern

サンディエゴ + 1.858.314.1171

Chao Wang is a registered patent agent focusing on patent prosecution in the chemistry and life science industries. Chao also advises clients on due diligence matters, including providing patentability and freedom-to-operate analysis. Chao has a wide range of technical experience in patent law that includes small molecule chemistry, bioconjugation, nanoparticle, gene delivery, diagnostic imaging, and radiopharmaceuticals.

Prior to commencing a career in patent law, Chao worked as a research scientist at the University of California San Francisco, where he focused on the development of radiopharmaceuticals for diagnosis of infectious diseases using positron emission tomography imaging. Chao was a postdoc fellow in the Department of Radiology at the University of California San Diego from 2017 to 2021, where he developed lipid and polymeric nanoparticles for use in cancer diagnosis and gene delivery. His Ph.D. thesis work focused on the synthesis of small molecule fluorophores for high-throughput measurement of enantiomeric excess of chiral compounds.

Chao has presented his scientific work at the American Chemical Society (ACS) National Meeting and at the World Molecular Imaging Congress (WMIC). He is a joint author of a dozen of highly ranked peer-reviewed chemistry and medicine journals. He is also co-inventor of two Patent Cooperation Treaty (PCT) patent applications.


  • Shiseido Americas acquires Dr. Dennis Gross Skincare for $450 millionJones Day advised Shiseido Americas Corporation, a subsidiary of Shiseido Co., Ltd., in the acquisition of DDG Skincare Holdings LLC, the owner of Dr. Dennis Gross Skincare, for $450 million in cash.
  • METiS Pharmaceuticals develops global patent portfolios related to lipid nanoparticles for mRNA-based gene therapiesJones Day is representing METiS Pharmaceuticals, Inc. in connection with the establishment of global patent portfolios related to lipid nanoparticles (LNP) and uses thereof in various mRNA-based gene therapies.
  • DNARx develops global patent portfolios for HEDGES™ gene therapy platformJones Day represents DNARx, LLC in the development and prosecution of global patent portfolios related to HEDGES™ (High-level Extended Duration Gene Express System), DNARx's proprietary non-viral gene therapy together with gene-based, highly combinatorial anti-pandemic monoclonal antibody cDNA-encoded protein delivery platform technology for the treatment of various unmet medical needs.